Dr Rosenzweig is EVP, Product Development and Strategy at Capstan. He is an experienced biopharmaceutical executive with extensive expertise and accomplishments in academic medicine and 20+ years in industry. Michael joined Capstan from RA Ventures where he was an EIR. Previously he served as an Associate Vice President at Merck Research Labs leading Oncology and Immunology Discovery. In this position, he played a pivotal role in building Merck’s oncology pipeline, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda® combination strategies. He led his team to progress more than 15 novel therapeutics into clinical development, a number of which are now in Phase 3 registration trials. Previously, he held discovery leadership roles at Immunext and Tolerx. Dr. Rosenzweig earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania.
